Based on CRI’s report, the global companion diagnostics market is projected to progress with a CAGR of 12.84% during the forecast period 2022-2028.
The prominent factors fueling the global market’s growth include a surge in medication reaction incidence, increasing cancer cases, and the growing use of precision medicines. Additionally, the ongoing research and investments in next generation gene-sequencing are expected to create affluent opportunities for the market.
However, a weak reimbursement framework and common cases of leakage in oncology companion diagnostics are expected to restrict the studied market’s growth over the forecast period.

REGIONAL OUTLOOK

The global companion diagnostics market covers North America, Asia-Pacific, Latin America, Europe, and the Middle East and Africa regions.
The Asia-Pacific is anticipated to emerge as the fastest-growing region over the forecast period. The region’s growth can be attributed to the tremendous growth in precision medicine technology. Moreover, initiatives undertaken to promote the R&D of precision medicine are supporting the market’s growth. In this regard, diagnostic and pharma companies are collaborating to offer an international platform to facilitate access to precision medicine. Thus, as mentioned above, these factors are expected to widen the scope and growth of the companion diagnostics market in the upcoming years.

COMPETITIVE OUTLOOK

The prominent companies thriving in the companion diagnostics market are Sysmex Corporation, Almac Group, Arup Laboratories, Biocartis, Abbott Laboratories, bioMerieux, GE Healthcare, Genomic Health, Danaher Corporation, Illumina Inc, Myriad Genetics, Qiagen, Roche Diagnostics, Thermo Fisher Scientific, and Agilent.
Abbott Laboratories is a pharmaceutical company engaged in developing and marketing healthcare products. It also offers diagnostic systems, neuro-modulation devices, medical devices, and other products. The company provides these products under multiple brand names, including Similar, Oxepa, Alinity, and FreeStyle, among others. It offers products to consumers, wholesalers, retailers, healthcare facilities, government agencies, laboratories, and ambulatory surgery centers. Abbott operates across North America, Latin America, the Middle and Africa, and Asia-Pacific.

TABLE OF CONTENTS

1. GLOBAL COMPANION DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
2.2. KEY INSIGHTS
2.2.1. COMMERCIAL SUCCESS OF PRECISION MEDICINE TREATMENT
2.2.2. ADOPTION OF PREDICTIVE BIOMARKERS
2.2.3. FUSION OF COMPUTER SCIENCE AND BIOLOGY
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. KEY BUYING IMPACT ANALYSIS
2.4.1. COST
2.4.2. AVAILABILITY
2.4.3. SENSITIVITY & SPECIFICITY
2.4.4. EFFICACY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. INDUSTRY COMPONENTS
2.8. REGULATORY FRAMEWORK
2.9. KEY MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT LAUNCHES
2.9.3. CONTRACTS & AGREEMENTS
2.10. MARKET DRIVERS
2.10.1. INCREASE IN INCIDENCE OF MEDICATION REACTIONS
2.10.2. INCREASING PREVALENCE OF CANCER CASES AND FATALITIES
2.10.3. RISING PREVALENCE OF PRECISION MEDICINES
2.11. MARKET CHALLENGES
2.11.1. WEAK REIMBURSEMENT FRAMEWORK
2.11.2. COMMON CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS
2.12. MARKET OPPORTUNITY
2.12.1. ONGOING RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING
3. GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK – BY MECHANISM
3.1. IN-SITU HYBRIDIZATION
3.2. POLYMERASE CHAIN REACTION
3.3. IMMUNOHISTOCHEMISTRY
3.4. NEXT GENERATION SEQUENCING
3.5. OTHER MECHANISMS
4. GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK – BY INDICATOR
4.1. ONCOLOGY
4.2. NEUROLOGY
4.3. INFECTIOUS DISEASES
4.4. OTHER INDICATORS
5. GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK – BY CONSUMER
5.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
5.2. REFERENCE LABORATORIES
5.3. OTHER CONSUMERS
6. GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK – BY COMMODITY
6.1. ASSAY KITS AND REAGENTS
6.2. SOFTWARE AND SERVICES
7. GLOBAL COMPANION DIAGNOSTICS MARKET – REGIONAL OUTLOOK
7.1. NORTH AMERICA
7.1.1. MARKET OUTLOOK BY MECHANISM
7.1.2. MARKET OUTLOOK BY INDICATOR
7.1.3. MARKET OUTLOOK BY CONSUMER
7.1.4. MARKET OUTLOOK BY COMMODITY
7.1.5. COUNTRY ANALYSIS
7.1.5.1. UNITED STATES
7.1.5.2. CANADA
7.2. EUROPE
7.2.1. MARKET OUTLOOK BY MECHANISM
7.2.2. MARKET OUTLOOK BY INDICATOR
7.2.3. MARKET OUTLOOK BY CONSUMER
7.2.4. MARKET OUTLOOK BY COMMODITY
7.2.5. COUNTRY ANALYSIS
7.2.5.1. UNITED KINGDOM
7.2.5.2. GERMANY
7.2.5.3. FRANCE
7.2.5.4. SPAIN
7.2.5.5. ITALY
7.2.5.6. POLAND
7.2.5.7. REST OF EUROPE
7.3. ASIA-PACIFIC
7.3.1. MARKET OUTLOOK BY MECHANISM
7.3.2. MARKET OUTLOOK BY INDICATOR
7.3.3. MARKET OUTLOOK BY CONSUMER
7.3.4. MARKET OUTLOOK BY COMMODITY
7.3.5. COUNTRY ANALYSIS
7.3.5.1. CHINA
7.3.5.2. JAPAN
7.3.5.3. INDIA
7.3.5.4. SOUTH KOREA
7.3.5.5. ASEAN COUNTRIES
7.3.5.6. AUSTRALIA & NEW ZEALAND
7.3.5.7. REST OF ASIA-PACIFIC
7.4. LATIN AMERICA
7.4.1. MARKET OUTLOOK BY MECHANISM
7.4.2. MARKET OUTLOOK BY INDICATOR
7.4.3. MARKET OUTLOOK BY CONSUMER
7.4.4. MARKET OUTLOOK BY COMMODITY
7.4.5. COUNTRY ANALYSIS
7.4.5.1. BRAZIL
7.4.5.2. MEXICO
7.4.5.3. REST OF LATIN AMERICA
7.5. MIDDLE EAST AND AFRICA
7.5.1. MARKET OUTLOOK BY MECHANISM
7.5.2. MARKET OUTLOOK BY INDICATOR
7.5.3. MARKET OUTLOOK BY CONSUMER
7.5.4. MARKET OUTLOOK BY COMMODITY
7.5.5. COUNTRY ANALYSIS
7.5.5.1. UNITED ARAB EMIRATES
7.5.5.2. SAUDI ARABIA
7.5.5.3. TURKEY
7.5.5.4. SOUTH AFRICA
7.5.5.5. REST OF MIDDLE EAST & AFRICA
8. COMPETITIVE LANDSCAPE
8.1. ABBOTT LABORATORIES
8.2. ALMAC GROUP
8.3. ARUP LABORATORIES
8.4. BIOCARTIS
8.5. BIOMERIEUX
8.6. DANAHER CORPORATION
8.7. GE HEALTHCARE
8.8. GENOMIC HEALTH
8.9. ILLUMINA INC
8.10. MYRIAD GENETICS
8.11. QIAGEN
8.12. ROCHE DIAGNOSTICS
8.13. SYSMEX CORPORATION
8.14. THERMO FISHER SCIENTIFIC
8.15. AGILENT
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY

LIST OF TABLES

TABLE 1: GLOBAL COMPANION DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF CONTRACTS & AGREEMENTS
TABLE 6: NUMBER OF CANCER PATIENTS IN 2020
TABLE 7: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 8: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 9: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 10: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 11: GLOBAL COMPANION DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 12: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 13: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 14: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 15: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 16: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 17: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 18: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 19: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 20: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 21: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 22: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 23: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 24: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 25: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 26: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 27: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 28: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 29: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 30: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 31: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 32: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 33: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 34: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 35: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 36: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: MARKET ATTRACTIVENESS INDEX
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: FDA FRAMEWORK
FIGURE 4: CDX LEAKAGE POINTS
FIGURE 5: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)
FIGURE 6: GLOBAL COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $ MILLION)
FIGURE 7: GLOBAL COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $ MILLION)
FIGURE 8: GLOBAL COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2028 (IN $ MILLION)
FIGURE 9: GLOBAL COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $ MILLION)
FIGURE 10: GLOBAL COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)
FIGURE 11: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)
FIGURE 12: GLOBAL COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 13: GLOBAL COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)
FIGURE 14: GLOBAL COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 15: GLOBAL COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)
FIGURE 16: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)
FIGURE 17: GLOBAL COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 18: GLOBAL COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $ MILLION)
FIGURE 19: GLOBAL COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)
FIGURE 20: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)
FIGURE 21: GLOBAL COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $ MILLION)
FIGURE 22: GLOBAL COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 23: GLOBAL COMPANION DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021 & 2028 (IN %)
FIGURE 24: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
FIGURE 25: UNITED STATES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 26: CANADA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 27: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
FIGURE 28: UNITED KINGDOM COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 29: GERMANY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 30: FRANCE COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 31: SPAIN COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 32: ITALY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 33: POLAND COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 34: REST OF EUROPE COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 35: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
FIGURE 36: CHINA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 37: JAPAN COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 38: INDIA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 39: SOUTH KOREA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 40: ASEAN COUNTRIES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 41: AUSTRALIA & NEW ZEALAND COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 42: REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 43: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
FIGURE 44: BRAZIL COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 45: MEXICO COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 46: REST OF LATIN AMERICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 47: MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET COUNTRY OUTLOOK, 2021
FIGURE 48: UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 49: SAUDI ARABIA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 50: TURKEY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 51: SOUTH AFRICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 52: REST OF MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

The post GLOBAL COMPANION DIAGNOSTICS MARKET 2022-2028 first appeared on CRI Report.

According to this report, the companion diagnostics market in North America is evaluated to attain a compound annual growth rate of 12.96% over the forecasting years 2022 to 2028. The United States and Canada shape the market in the region.
In Canada, several public and private initiatives are expected to widen the scope of the studied market, despite limited healthcare policy. For instance, the Alliance for Innovation in Molecular Diagnostics is working to improve the companion diagnostics innovation environment. The initiatives also aim to decrease the lack of clarity on how decision-makers prioritize the CDx tests by highlighting the interprovincial regulations that deter CDx development and adoption.
Furthermore, HTA agencies, government agencies, and hospitals strive to promote CDx applications by providing reimbursements. Above all, innovative clinical trials, increased R&D investments, and healthcare plans are anticipated to fuel the Canadian companion diagnostics market’s growth over the forecast period.
In the US, the rapid evolution of diagnostics technologies and investments are increasing the demand for advanced diagnostic testing. Moreover, the recent developments favoring comprehensive CDx tests to gain the necessary information to make therapeutic decisions are responsible for propelling the companion diagnostics market on a growth path.

COMPETITIVE OUTLOOK

The notable companies thriving in the companion diagnostics market include Almac Group, GE Healthcare, Roche Diagnostics, Sysmex Corporation, and Abbott Laboratories.

TABLE OF CONTENTS

1. NORTH AMERICA COMPANION DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
2.2. KEY INSIGHTS
2.2.1. COMMERCIAL SUCCESS OF PRECISION MEDICINE TREATMENT
2.2.2. ADOPTION OF PREDICTIVE BIOMARKERS
2.2.3. FUSION OF COMPUTER SCIENCE AND BIOLOGY
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. KEY BUYING IMPACT ANALYSIS
2.4.1. COST
2.4.2. AVAILABILITY
2.4.3. SENSITIVITY & SPECIFICITY
2.4.4. EFFICACY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. INDUSTRY COMPONENTS
2.8. REGULATORY FRAMEWORK
2.9. KEY MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT LAUNCHES
2.9.3. CONTRACTS & AGREEMENTS
2.10. MARKET DRIVERS
2.10.1. INCREASE IN INCIDENCE OF MEDICATION REACTIONS
2.10.2. INCREASING PREVALENCE OF CANCER CASES AND FATALITIES
2.10.3. RISING PREVALENCE OF PRECISION MEDICINES
2.11. MARKET CHALLENGES
2.11.1. WEAK REIMBURSEMENT FRAMEWORK
2.11.2. COMMON CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS
2.12. MARKET OPPORTUNITY
2.12.1. ONGOING RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING
3. NORTH AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY MECHANISM
3.1. IN-SITU HYBRIDIZATION
3.2. POLYMERASE CHAIN REACTION
3.3. IMMUNOHISTOCHEMISTRY
3.4. NEXT GENERATION SEQUENCING
3.5. OTHER MECHANISMS
4. NORTH AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY INDICATOR
4.1. ONCOLOGY
4.2. NEUROLOGY
4.3. INFECTIOUS DISEASES
4.4. OTHER INDICATORS
5. NORTH AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY CONSUMER
5.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
5.2. REFERENCE LABORATORIES
5.3. OTHER CONSUMERS
6. NORTH AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY COMMODITY
6.1. ASSAY KITS AND REAGENTS
6.2. SOFTWARE AND SERVICES
7. NORTH AMERICA COMPANION DIAGNOSTICS MARKET – COUNTRY OUTLOOK
7.1. UNITED STATES
7.2. CANADA
8. COMPETITIVE LANDSCAPE
8.1. ABBOTT LABORATORIES
8.2. ALMAC GROUP
8.3. ARUP LABORATORIES
8.4. BIOCARTIS
8.5. BIOMERIEUX
8.6. DANAHER CORPORATION
8.7. GE HEALTHCARE
8.8. GENOMIC HEALTH
8.9. ILLUMINA INC
8.10. MYRIAD GENETICS
8.11. QIAGEN
8.12. ROCHE DIAGNOSTICS
8.13. SYSMEX CORPORATION
8.14. THERMO FISHER SCIENTIFIC
8.15. AGILENT
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY

LIST OF TABLES

TABLE 1: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF CONTRACTS & AGREEMENTS
TABLE 6: NUMBER OF CANCER PATIENTS IN 2020
TABLE 7: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 8: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 9: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 11: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: MARKET ATTRACTIVENESS INDEX
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: FDA FRAMEWORK
FIGURE 4: CDX LEAKAGE POINTS
FIGURE 5: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)
FIGURE 6: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $ MILLION)
FIGURE 7: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $ MILLION)
FIGURE 8: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2028 (IN $ MILLION)
FIGURE 9: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $ MILLION)
FIGURE 10: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)
FIGURE 11: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)
FIGURE 12: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 13: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)
FIGURE 14: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 15: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)
FIGURE 16: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)
FIGURE 17: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 18: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $ MILLION)
FIGURE 19: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)
FIGURE 20: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)
FIGURE 21: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $ MILLION)
FIGURE 22: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 23: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 24: UNITED STATES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 25: CANADA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

The post NORTH AMERICA COMPANION DIAGNOSTICS MARKET 2022-2028 first appeared on CRI Report.

CRI’s research report insinuates that the Latin American companion diagnostics market is expected to register growth at a compound annual growth rate of 12.10% during the forecasting years 2022-2028. Mexico, Brazil, and Rest of Latin America are considered in the region.
In Mexico, initiatives undertaken to reduce approval time for clinical trials are anticipated to surge the adoption of companion diagnostics devices. For instance, the government amended various acts to accelerate clinical trials. Besides this, the Federal Commission for the Protection against Sanitary Risk is working on various aspects to decrease the hurdles faced during these trials. Moreover, it aims to increase the number of pharmaceutical companies conducting clinical trials. Thus, these factors are expected to contribute to the expansion of the companion diagnostics market.
In Rest of Latin America, countries like Argentina, Peru, Chile, and Columbia are expected to witness consistent growth over the forecast period. As per estimates, the in-vitro and molecular diagnostics industry is expanding at a rapid pace, which is estimated to augment the companion diagnostics market’s growth. In Argentina, the rising acceptance of advanced diagnostic technologies by physicians is among the major factors supporting the studied market’s growth.

COMPETITIVE OUTLOOK

The notable companies in the companion diagnostics market include Almac Group, Biocartis, Abbott Laboratories, Danaher Corporation, and GE Healthcare.

TABLE OF CONTENTS

1. LATIN AMERICA COMPANION DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
2.2. KEY INSIGHTS
2.2.1. COMMERCIAL SUCCESS OF PRECISION MEDICINE TREATMENT
2.2.2. ADOPTION OF PREDICTIVE BIOMARKERS
2.2.3. FUSION OF COMPUTER SCIENCE AND BIOLOGY
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. KEY BUYING IMPACT ANALYSIS
2.4.1. COST
2.4.2. AVAILABILITY
2.4.3. SENSITIVITY & SPECIFICITY
2.4.4. EFFICACY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. INDUSTRY COMPONENTS
2.8. REGULATORY FRAMEWORK
2.9. KEY MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT LAUNCHES
2.9.3. CONTRACTS & AGREEMENTS
2.10. MARKET DRIVERS
2.10.1. INCREASE IN INCIDENCE OF MEDICATION REACTIONS
2.10.2. INCREASING PREVALENCE OF CANCER CASES AND FATALITIES
2.10.3. RISING PREVALENCE OF PRECISION MEDICINES
2.11. MARKET CHALLENGES
2.11.1. WEAK REIMBURSEMENT FRAMEWORK
2.11.2. COMMON CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS
2.12. MARKET OPPORTUNITY
2.12.1. ONGOING RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING
3. LATIN AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY MECHANISM
3.1. IN-SITU HYBRIDIZATION
3.2. POLYMERASE CHAIN REACTION
3.3. IMMUNOHISTOCHEMISTRY
3.4. NEXT GENERATION SEQUENCING
3.5. OTHER MECHANISMS
4. LATIN AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY INDICATOR
4.1. ONCOLOGY
4.2. NEUROLOGY
4.3. INFECTIOUS DISEASES
4.4. OTHER INDICATORS
5. LATIN AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY CONSUMER
5.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
5.2. REFERENCE LABORATORIES
5.3. OTHER CONSUMERS
6. LATIN AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY COMMODITY
6.1. ASSAY KITS AND REAGENTS
6.2. SOFTWARE AND SERVICES
7. LATIN AMERICA COMPANION DIAGNOSTICS MARKET – COUNTRY OUTLOOK
7.1. BRAZIL
7.2. MEXICO
7.3. REST OF LATIN AMERICA
8. COMPETITIVE LANDSCAPE
8.1. ABBOTT LABORATORIES
8.2. ALMAC GROUP
8.3. ARUP LABORATORIES
8.4. BIOCARTIS
8.5. BIOMERIEUX
8.6. DANAHER CORPORATION
8.7. GE HEALTHCARE
8.8. GENOMIC HEALTH
8.9. ILLUMINA INC
8.10. MYRIAD GENETICS
8.11. QIAGEN
8.12. ROCHE DIAGNOSTICS
8.13. SYSMEX CORPORATION
8.14. THERMO FISHER SCIENTIFIC
8.15. AGILENT
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY

LIST OF TABLES

TABLE 1: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF CONTRACTS & AGREEMENTS
TABLE 6: NUMBER OF CANCER PATIENTS IN 2020
TABLE 7: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 8: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 9: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 10: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 11: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: MARKET ATTRACTIVENESS INDEX
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: FDA FRAMEWORK
FIGURE 4: CDX LEAKAGE POINTS
FIGURE 5: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)
FIGURE 6: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $ MILLION)
FIGURE 7: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $ MILLION)
FIGURE 8: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2028 (IN $ MILLION)
FIGURE 9: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $ MILLION)
FIGURE 10: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)
FIGURE 11: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)
FIGURE 12: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 13: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)
FIGURE 14: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 15: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)
FIGURE 16: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)
FIGURE 17: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 18: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $ MILLION)
FIGURE 19: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)
FIGURE 20: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)
FIGURE 21: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $ MILLION)
FIGURE 22: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 23: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 24: BRAZIL COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 25: MEXICO COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 26: REST OF LATIN AMERICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

The post LATIN AMERICA COMPANION DIAGNOSTICS MARKET 2022-2028 first appeared on CRI Report.

CRI’s report suggests that the Middle East and Africa companion diagnostics market is estimated to progress at a compound annual growth rate of 12.53% during the forecast years 2022-2028. Israel, South Africa, the UAE, Saudi Arabia, Turkey, and Rest of Middle East & Africa are studied in the given region.
Over the years, precision medicine has gained significant traction in the United Arab Emirates. In this regard, the government has restructured the reimbursement and pricing systems to gain from the potential of drug-diagnostic pairings. As a result, several companies have revised their strategies to create value for stakeholders, including patients, policymakers, and physicians. Therefore, such efforts to increase the adoption of precision medicine are expected to create lucrative opportunities for the companion diagnostics market.
On the other hand, the companion diagnostics market is at a nascent stage in South Africa. This is because professionals are unable to fully ascertain the potential of quick, accurate, and timely therapeutic intervention. Nevertheless, several manufacturers are targeting the market, owing to the rise in cancer cases. In this regard, a new regulatory authority was formed to oversee the sale of drugs and medical devices. These factors are thus expected to open new avenues for the companion diagnostics market in the upcoming years.

COMPETITIVE OUTLOOK

Major firms in the companion diagnostics market consist of Abbott Laboratories, Illumina Inc, Agilent, Qiagen, and Almac Group.

TABLE OF CONTENTS

1. MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
2.2. KEY INSIGHTS
2.2.1. COMMERCIAL SUCCESS OF PRECISION MEDICINE TREATMENT
2.2.2. ADOPTION OF PREDICTIVE BIOMARKERS
2.2.3. FUSION OF COMPUTER SCIENCE AND BIOLOGY
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. KEY BUYING IMPACT ANALYSIS
2.4.1. COST
2.4.2. AVAILABILITY
2.4.3. SENSITIVITY & SPECIFICITY
2.4.4. EFFICACY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. INDUSTRY COMPONENTS
2.8. REGULATORY FRAMEWORK
2.9. KEY MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT LAUNCHES
2.9.3. CONTRACTS & AGREEMENTS
2.10. MARKET DRIVERS
2.10.1. INCREASE IN INCIDENCE OF MEDICATION REACTIONS
2.10.2. INCREASING PREVALENCE OF CANCER CASES AND FATALITIES
2.10.3. RISING PREVALENCE OF PRECISION MEDICINES
2.11. MARKET CHALLENGES
2.11.1. WEAK REIMBURSEMENT FRAMEWORK
2.11.2. COMMON CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS
2.12. MARKET OPPORTUNITY
2.12.1. ONGOING RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING
3. MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY MECHANISM
3.1. IN-SITU HYBRIDIZATION
3.2. POLYMERASE CHAIN REACTION
3.3. IMMUNOHISTOCHEMISTRY
3.4. NEXT GENERATION SEQUENCING
3.5. OTHER MECHANISMS
4. MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY INDICATOR
4.1. ONCOLOGY
4.2. NEUROLOGY
4.3. INFECTIOUS DISEASES
4.4. OTHER INDICATORS
5. MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY CONSUMER
5.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
5.2. REFERENCE LABORATORIES
5.3. OTHER CONSUMERS
6. MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET OUTLOOK – BY COMMODITY
6.1. ASSAY KITS AND REAGENTS
6.2. SOFTWARE AND SERVICES
7. MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET – COUNTRY OUTLOOK
7.1. UNITED ARAB EMIRATES
7.2. SAUDI ARABIA
7.3. TURKEY
7.4. SOUTH AFRICA
7.5. REST OF MIDDLE EAST & AFRICA
8. COMPETITIVE LANDSCAPE
8.1. ABBOTT LABORATORIES
8.2. ALMAC GROUP
8.3. ARUP LABORATORIES
8.4. BIOCARTIS
8.5. BIOMERIEUX
8.6. DANAHER CORPORATION
8.7. GE HEALTHCARE
8.8. GENOMIC HEALTH
8.9. ILLUMINA INC
8.10. MYRIAD GENETICS
8.11. QIAGEN
8.12. ROCHE DIAGNOSTICS
8.13. SYSMEX CORPORATION
8.14. THERMO FISHER SCIENTIFIC
8.15. AGILENT
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY

LIST OF TABLES

TABLE 1: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF CONTRACTS & AGREEMENTS
TABLE 6: NUMBER OF CANCER PATIENTS IN 2020
TABLE 7: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 8: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 9: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 10: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 11: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: MARKET ATTRACTIVENESS INDEX
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: FDA FRAMEWORK
FIGURE 4: CDX LEAKAGE POINTS
FIGURE 5: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)
FIGURE 6: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $ MILLION)
FIGURE 7: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $ MILLION)
FIGURE 8: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2028 (IN $ MILLION)
FIGURE 9: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $ MILLION)
FIGURE 10: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)
FIGURE 11: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)
FIGURE 12: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 13: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)
FIGURE 14: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 15: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)
FIGURE 16: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)
FIGURE 17: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 18: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $ MILLION)
FIGURE 19: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)
FIGURE 20: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)
FIGURE 21: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $ MILLION)
FIGURE 22: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 23: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 24: UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 25: SAUDI ARABIA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 26: TURKEY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 27: SOUTH AFRICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 28: REST OF MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

The post MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET 2022-2028 first appeared on CRI Report.

CRI’s report infers that the companion diagnostics market in Europe is deemed to advance at a CAGR of 12.61% in value during the forecast years 2022-2028. Italy, Spain, France, Germany, Poland, the United Kingdom, and the Rest of Europe are evaluated in the market report.
In France, the majority of the population is supported by statutory health insurance overseen by the Hauté Autorite de Santé (HAS). In this regard, the national healthcare system in the country is considered to be considerate as it aims to reduce healthcare expenditure. The reduction in healthcare expenditure will ultimately reduce excess government spending. Due to high reimbursement coverage, the penetration of CDx is high in the country. Thus, such developments support the companion diagnostics market’s growth across the country.
Furthermore, Spain has been witnessing economic restraints over the past few years. This has made it imperative to reduce healthcare expenses. In this regard, CDx is executed in the outpatient hospital site. On the other hand, hospitals directly negotiate with the manufacturer. The hospital funding system relies on the global budget since reimbursement coding is unavailable for CDx. Nevertheless, the rising efforts to reduce healthcare expenses will increase the need for cost-effective technologies for diagnostics, opening new avenues for the market.

COMPETITIVE OUTLOOK

The prominent companies in the companion diagnostics market consist of Abbott Laboratories, Arup Laboratories, Biocartis, Almac Group, GE Healthcare, and Roche Diagnostics.

TABLE OF CONTENTS

1. EUROPE COMPANION DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
2.2. KEY INSIGHTS
2.2.1. COMMERCIAL SUCCESS OF PRECISION MEDICINE TREATMENT
2.2.2. ADOPTION OF PREDICTIVE BIOMARKERS
2.2.3. FUSION OF COMPUTER SCIENCE AND BIOLOGY
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. KEY BUYING IMPACT ANALYSIS
2.4.1. COST
2.4.2. AVAILABILITY
2.4.3. SENSITIVITY & SPECIFICITY
2.4.4. EFFICACY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. INDUSTRY COMPONENTS
2.8. REGULATORY FRAMEWORK
2.9. KEY MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT LAUNCHES
2.9.3. CONTRACTS & AGREEMENTS
2.10. MARKET DRIVERS
2.10.1. INCREASE IN INCIDENCE OF MEDICATION REACTIONS
2.10.2. INCREASING PREVALENCE OF CANCER CASES AND FATALITIES
2.10.3. RISING PREVALENCE OF PRECISION MEDICINES
2.11. MARKET CHALLENGES
2.11.1. WEAK REIMBURSEMENT FRAMEWORK
2.11.2. COMMON CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS
2.12. MARKET OPPORTUNITY
2.12.1. ONGOING RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING
3. EUROPE COMPANION DIAGNOSTICS MARKET OUTLOOK – BY MECHANISM
3.1. IN-SITU HYBRIDIZATION
3.2. POLYMERASE CHAIN REACTION
3.3. IMMUNOHISTOCHEMISTRY
3.4. NEXT GENERATION SEQUENCING
3.5. OTHER MECHANISMS
4. EUROPE COMPANION DIAGNOSTICS MARKET OUTLOOK – BY INDICATOR
4.1. ONCOLOGY
4.2. NEUROLOGY
4.3. INFECTIOUS DISEASES
4.4. OTHER INDICATORS
5. EUROPE COMPANION DIAGNOSTICS MARKET OUTLOOK – BY CONSUMER
5.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
5.2. REFERENCE LABORATORIES
5.3. OTHER CONSUMERS
6. EUROPE COMPANION DIAGNOSTICS MARKET OUTLOOK – BY COMMODITY
6.1. ASSAY KITS AND REAGENTS
6.2. SOFTWARE AND SERVICES
7. EUROPE COMPANION DIAGNOSTICS MARKET – COUNTRY OUTLOOK
7.1. UNITED KINGDOM
7.2. GERMANY
7.3. FRANCE
7.4. SPAIN
7.5. ITALY
7.6. POLAND
7.7. REST OF EUROPE
8. COMPETITIVE LANDSCAPE
8.1. ABBOTT LABORATORIES
8.2. ALMAC GROUP
8.3. ARUP LABORATORIES
8.4. BIOCARTIS
8.5. BIOMERIEUX
8.6. DANAHER CORPORATION
8.7. GE HEALTHCARE
8.8. GENOMIC HEALTH
8.9. ILLUMINA INC
8.10. MYRIAD GENETICS
8.11. QIAGEN
8.12. ROCHE DIAGNOSTICS
8.13. SYSMEX CORPORATION
8.14. THERMO FISHER SCIENTIFIC
8.15. AGILENT
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY

LIST OF TABLES

TABLE 1: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF CONTRACTS & AGREEMENTS
TABLE 6: NUMBER OF CANCER PATIENTS IN 2020
TABLE 7: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 8: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 9: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 10: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 11: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: MARKET ATTRACTIVENESS INDEX
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: FDA FRAMEWORK
FIGURE 4: CDX LEAKAGE POINTS
FIGURE 5: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)
FIGURE 6: EUROPE COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $ MILLION)
FIGURE 7: EUROPE COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $ MILLION)
FIGURE 8: EUROPE COMPANION DIAGNOSTICS MARKET, BY IMMUNOHOSTOCHEMISTRY, 2022-2028 (IN $ MILLION)
FIGURE 9: EUROPE COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $ MILLION)
FIGURE 10: EUROPE COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)
FIGURE 11: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)
FIGURE 12: EUROPE COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 13: EUROPE COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)
FIGURE 14: EUROPE COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 15: EUROPE COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)
FIGURE 16: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)
FIGURE 17: EUROPE COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 18: EUROPE COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $ MILLION)
FIGURE 19: EUROPE COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)
FIGURE 20: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)
FIGURE 21: EUROPE COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $ MILLION)
FIGURE 22: EUROPE COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 23: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 24: UNITED KINGDOM COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 25: GERMANY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 26: FRANCE COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 27: SPAIN COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 28: ITALY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 29: POLAND COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 30: REST OF EUROPE COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

The post EUROPE COMPANION DIAGNOSTICS MARKET 2022-2028 first appeared on CRI Report.